AbbVie (NYSE:ABBV) Stock Keeps Buy Rating at Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating reissued by investment analysts at Guggenheim in a research note issued to investors on Friday, Benzinga reports. They currently have a $288.00 target price on the stock. Guggenheim’s price target suggests a potential upside of 4.87% from the company’s previous close.

A number of other research firms have also recently commented on ABBV. Piper Sandler raised their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. BNP Paribas Exane lifted their price target on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Oppenheimer lifted their price objective on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, Leerink Partners raised their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $276.64.

AbbVie Trading Up 0.8%

Shares of AbbVie stock traded up $2.20 during trading hours on Friday, reaching $274.62. The stock had a trading volume of 447,833 shares, compared to its average volume of 6,398,565. The firm has a market capitalization of $485.20 billion, a PE ratio of 77.48, a PEG ratio of 1.23 and a beta of 0.24. The stock’s 50 day moving average is $258.56 and its 200 day moving average is $236.35. AbbVie has a twelve month low of $190.75 and a twelve month high of $276.61.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the business earned $2.97 earnings per share. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts predict that AbbVie will post 14.01 earnings per share for the current year.

Insider Activity

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently modified their holdings of ABBV. State Street Corp boosted its stake in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the period. Legal & General Group Plc purchased a new stake in AbbVie during the 2nd quarter valued at about $2,905,952,000. Deutsche Bank AG lifted its holdings in AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares in the last quarter. Finally, Amundi grew its stake in shares of AbbVie by 2.4% in the first quarter. Amundi now owns 10,698,095 shares of the company’s stock worth $2,326,728,000 after acquiring an additional 247,689 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts raised targets and reaffirmed bullish ratings. Guggenheim reaffirmed its “buy” rating with a $288 price target, while JPMorgan raised its target to $300 and maintained an “overweight” rating. Cantor Fitzgerald also lifted its target to $290 and kept an “overweight” rating. The revisions indicate continued confidence in AbbVie’s earnings outlook and growth prospects.
• Positive Sentiment: Temab-A received two FDA Breakthrough Therapy Designations. AbbVie’s telisotuzumab adizutecan (Temab-A, or ABBV-400) received the designations for potential use in colorectal cancer and non-small cell lung cancer. The FDA status may accelerate development and review, strengthening the perceived value of AbbVie’s oncology pipeline. FDA Grants Breakthrough Therapy Designations to AbbVie’s Temab-A
• Positive Sentiment: Additional oncology data supported pipeline optimism. An AbbVie and Genmab combination involving epcoritamab reportedly reduced the risk of progression or death by 51% in diffuse large B-cell lymphoma, providing another favorable signal for AbbVie’s cancer portfolio.
• Positive Sentiment: Momentum has pushed ABBV to new one-year highs. The stock recently set consecutive 52-week highs, suggesting that analyst upgrades and pipeline news are reinforcing positive investor sentiment.
• Neutral Sentiment: Valuation and expectations remain important risks. AbbVie is trading near its 12-month high with a relatively elevated price-to-earnings ratio, so further gains may depend on the company delivering against strong earnings and pipeline expectations. Recent coverage also noted mixed growth outlooks across large pharmaceutical companies, despite higher price targets.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.